Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2010

01-08-2010 | Article

Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe

Author: S. P. Hawser

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2010

Login to get access

Abstract

A total of 206 clinical isolates of Finegoldia magna were collected during the period 2007–2009 from six European countries. The majority of isolates were from body fluids (n = 83; 40.3%) or wounds (n = 82; 39.8%). All isolates were susceptible to tigecycline, meropenem, metronidazole and piperacillin / tazobactam, though susceptibility to penicillin (86.4–87.4%) and clindamycin (78.2–93.3%) were more variable.
Literature
1.
go back to reference Higaki S, Morohashi M (2003) Characteristics of anaerobes from skin specimens. Drugs Exp Clin Res 29:153–155PubMed Higaki S, Morohashi M (2003) Characteristics of anaerobes from skin specimens. Drugs Exp Clin Res 29:153–155PubMed
2.
go back to reference Murdoch DA (1998) Gram-positive anaerobic cocci. Clin Microbiol Rev 11:81–120PubMed Murdoch DA (1998) Gram-positive anaerobic cocci. Clin Microbiol Rev 11:81–120PubMed
3.
go back to reference Bemer MJ, Touchais P, Asseray N, Corvec S (2009) Recurrent abscesses due to Finegoldia magna, Dermabacter hominis and Staphylococcus aureus in an immunocompetent patient. Anaerobe 15:201–203CrossRefPubMed Bemer MJ, Touchais P, Asseray N, Corvec S (2009) Recurrent abscesses due to Finegoldia magna, Dermabacter hominis and Staphylococcus aureus in an immunocompetent patient. Anaerobe 15:201–203CrossRefPubMed
4.
go back to reference van der Vorm EC, Dondorp AM, van Ketel RJ, Dankert J (2000) Apparent culture-negative prosthetic valve endocarditis caused by Peptostreptococcus magnus. J Clin Microbiol 38:4640–4642PubMed van der Vorm EC, Dondorp AM, van Ketel RJ, Dankert J (2000) Apparent culture-negative prosthetic valve endocarditis caused by Peptostreptococcus magnus. J Clin Microbiol 38:4640–4642PubMed
5.
go back to reference Bassetti S, Laifer G, Goy G, Fluckiger U, Frei R (2003) Endocarditis caused by Finegoldia magna (formerly Peptostreptococcus magnus): diagnosis depends on the blood culture system used. Diagn Microbiol Infect Dis 47:359–3CrossRefPubMed Bassetti S, Laifer G, Goy G, Fluckiger U, Frei R (2003) Endocarditis caused by Finegoldia magna (formerly Peptostreptococcus magnus): diagnosis depends on the blood culture system used. Diagn Microbiol Infect Dis 47:359–3CrossRefPubMed
6.
go back to reference Fournier PE, La MV, Casalta JP, Richet H, Collart F, Raoult D (2008) Finegoldia magna, an early post-operative cause of infectious endocarditis: report of two cases and review of the literature. Anaerobe 14:310–312CrossRefPubMed Fournier PE, La MV, Casalta JP, Richet H, Collart F, Raoult D (2008) Finegoldia magna, an early post-operative cause of infectious endocarditis: report of two cases and review of the literature. Anaerobe 14:310–312CrossRefPubMed
7.
go back to reference Clinical and Laboratory Standards Institute (2007) Methods for antimicrobial susceptibility tests of anaerobic bacteria, 7th edition. Approved standard M11-A7. CLSI, Wayne, Pennsylvania, USA Clinical and Laboratory Standards Institute (2007) Methods for antimicrobial susceptibility tests of anaerobic bacteria, 7th edition. Approved standard M11-A7. CLSI, Wayne, Pennsylvania, USA
10.
go back to reference Nagy E, Dowzicky MJ (2010) In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 42:33–38CrossRefPubMed Nagy E, Dowzicky MJ (2010) In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 42:33–38CrossRefPubMed
Metadata
Title
Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe
Author
S. P. Hawser
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2010
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-0962-7

Other articles of this Issue 8/2010

European Journal of Clinical Microbiology & Infectious Diseases 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.